1-2 of 2
Joel S. Parker, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genomics Reveal Potential Biomarkers of Response to Pembrolizumab after High Dose Cytarabine in an Ongoing Phase II Trial in Relapsed/Refractory AML

Joshua F Zeidner, MD, Benjamin G. Vincent, MD, Anastasia Ivanova, PhD, Matthew C Foster, MD, Catherine C. Coombs, MD, Katarzyna Jamieson, MD, Hendrik W. Van Deventer, MD, Laura Blanchard, Cassiopeia Frank, Sean Gallagher, Melissa Matson, AGPCNP-BC, Katherine Pepin, Lori Vaught, Nancy Vogler, Kelsey Miller, Laurie Betts, Karen McKinnon, PhD, Dante S. Bortone, PhD, Joel S. Parker, PhD, Leo Luznik, MD, Ivana Gojo, MD, Jonathan S Serody, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4054.
https://doi.org/10.1182/blood-2018-99-116608
Published: 2018
Journal Articles

Discovery of an Immune-Driven Gene Expression Signature That Predicts for Clinical Benefit to CC-122 in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Alberto Risueño, PhD, Patrick R. Hagner, PhD, Celia Fontanillo, PhD, Amira Djebbari, DSc, Joel S. Parker, PhD, Clifton P. Drew, PhD, Fadi Towfic, PhD, Michael Pourdehnad, MD, Anita K. Gandhi, PhD, Matthew Trotter, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2830.
https://doi.org/10.1182/blood.V130.Suppl_1.2830.2830
Published: 2017